Pregabalin Solution
Product Images NDC 59762-1576

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 59762-1576). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Pregabalin 01)

The text is describing a blood test result for serum creatinine. It includes the values of 72 (unit not specified) and a reference range of 0.85 for female patients. However, there seems to be some non-English characters and symbols that make the text not perfectly readable.*

FDA Label Image

Chemical Structure (Pregabalin 02)

FDA Label Image

Figure 1 (Pregabalin 03)

FDA Label Image

Figure 2 (Pregabalin 04)

The table shows the percentage of patients who have shown improvement after taking Pregabalin 106mg three times a day. The improvement is measured based on the pain from baseline, and the percentage of patients improved is shown as 100%, 20%, and 10%. There is additional unclear text on the table that cannot be understood.*

FDA Label Image

Figure 3 (Pregabalin 05)

FDA Label Image

Figure 4 (Pregabalin 06)

This text presents results from a study on pain management using medication. The three medications tested were Pregabalin 200 mg three times a day, Pregabalin 100mg three times a day and Placebo. The numbers (50, 210, 220, 230, 2, 2, 260, 270, 280, 230, 100) represent the percentage of improvement in pain from baseline. The numbers under the heading "Percent of Patients Improved" appear to be unreadable.*

FDA Label Image

Figure 5 (Pregabalin 07)

This appears to be a table showing the percentage of patients who experienced improvement in pain from baseline while taking either Pregabalin 100mg three times a day, Pregabalin 200mg three times a day, or the placebo. However, the percentages are not accurately readable and appear to be distorted.*

FDA Label Image

Figure 6 (Pregabalin 08)

FDA Label Image

Figure 7 (Pregabalin 09)

FDA Label Image

Figure 8 (Pregabalin 10)

This appears to be a table that shows the responder rate (%) for three different treatment options, as well as a placebo. The treatment options are not clearly indicated, but it seems that they are associated with doses of 2.5 mg/kg/day and 10 mg/kg/day. The responder rates range from 22.6% to 40.6%, with the placebo having the lowest responder rate. The numbers listed at the bottom may be participant counts or some other metric related to the study.*

FDA Label Image

Figure 9 (Pregabalin 11)

This appears to be a chart showing the percentage of patients who experienced improvement in their pain levels after taking different doses of Pregabalin. The chart compares the effectiveness of a 600mg daily dose, a 450mg daily dose, a 300mg daily dose, and a placebo. The chart also shows the percentage improvement in pain from the baseline for each of the different doses.*

FDA Label Image

Figure 10 (Pregabalin 12)

This appears to be a graph displaying the estimated percentage of subjects without LTR (no definition of what LTR means was given) over a period of 180 days. The graph includes two lines, one for "Placsbo" and one for "Pregabain". The x-axis displays days, with ticks at 20, 40, 60, 80, 100, 120, 140, 160, and 180. The y-axis displays the estimated percentage of subjects without LTR, with ticks at 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100%.*

FDA Label Image

Figure 11 (Pregabalin 13)

This table appears to show the percentage of subjects who improved after taking the drug Pregabalin compared to a placebo. The top row indicates the percentage of subjects who improved, with 100% being the highest. The left column shows various numbers associated with the study. The text "Percent Improved from Baseline to Week 12 BOCF" suggests that the study was 12 weeks long and that improvement was measured from the beginning of the study (baseline) to the end. Overall, this table provides information on the effectiveness of Pregabalin in improving the symptoms of a specific condition.*

FDA Label Image

Figure 12 (Pregabalin 14)

FDA Label Image

Logo (Pregabalin 15)

This is a description of the distributor of Greenstone brand, Greenstone LLC, based in Peapack, NJ 07977.*

FDA Label Image

Logo (Pregabalin 15a)

This is a description of a brand called Greenstone, which is distributed by Greenstone LLC located in Peapack, NJ 07977.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

This text provides important information regarding the storage recommended for pregabalin capsules. It is advised to store the capsules at a temperature of 25°C (77°F) with permitted excursions to 15-30°C (59-86°F). The drug should be dispensed in a tight container that meets the USP standard and is also child-resistant. The dosage and usage information should be obtained from the prescribing information that accompanies the capsules. Each capsule contains 25mg pregabalin. The capsules are distributed by Greenstone LLC in Peapack, NJ and are made in Singapore. The text also shows relevant codes like FPO UPC, NDC, GTIN, and PAA103838.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

This is a medication information label indicating the storage condition, dosage, and use of pregabalin capsules containing 50mg per capsule. It also indicates the distributor, Greenstone LLC and the country of origin, Singapore. Additionally, it shows the manufacturer's identification number, product number, bar code, and dosage information.*

FDA Label Image

Principal Display Panel (75 mg Capsule Bottle Label)

This is a medication information sheet about pregabalin capsules, which come in 75mg strength. It provides instructions on storage temperatures, dosage, and prescription information. The medicine is distributed by Greenstone LLC and made in Singapore. Additionally, the packaging and containers must be child-resistant, and dispensing with the accompanying medication guide is mandatory. The GTIN code is PAA103840.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Store pregabalin capsules at room temperature of 25°C (77°F) with possible excursions from 15-30°C (59-86°F). The product should be kept in child-resistant containers. Each capsule contains 100 mg of pregabalin, and the accompanying prescribing information should be consulted for dosage and use. The medication should always be dispensed with medication guidance. Greenstone LLC distributes the product, and it is made in Singapore. The product's barcode is 00359762134813, and the NDC is 59762-1348-1.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

This is a medication containing 150mg pregabalin per capsule. It should be stored at a temperature between 15-30°C (59-86°F) and dispensed in containers resistant to light. Further instructions and dosage information can be found in the prescribing documentation. The medication is distributed by Greenstone LLC and each package contains 90 capsules. The NDC code for this medication is 59762-1351-1 and it is manufactured in Singapore under the Greenstone® brand.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

This is a medication called Pregabalin that comes in a capsule form with 200 mg. It should be stored at a temperature between 59-86°F and dispensed in the provided airtight container. Dosage and usage information can be found in the accompanying prescribing information. It is distributed by Greenstone LLC from Peapack, NJ, and was made in Singapore. It comes in a pack of 90 capsules with an NDC code of 59762-1354-1. Always dispense with medication guide. No available lot/exp or GTIN number.*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

This is a prescription medication containing 225 mg of pregabalin per capsule. It should be stored at 25°C (77°F), but excursions between 15-30°C (59-86°F) are permitted. The medication should be dispensed in tight, child-resistant containers. More information about dosage and use can be found in the accompanying prescribing information. The medication is distributed by Greenstone LLC and comes in a bottle of 90 capsules. The NDC number is 59762-1360-1, and the medication guide should always be dispensed with the capsules. The GTIN number is not available due to errors.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

This is a medication packaging of Pregabalin capsules containing 300mg per capsule. The capsules should be stored at 25°C (77°F) with excursions permitted between 15-30°C (9-86°F) and must be always dispensed in child-resistant containers. The product is distributed by Greenstone LLC and made in Singapore. Further dosage and usage instructions can be found in the accompanying prescribing information. The National Drug Code (NDC) for this product is 59762-1364-1. The package includes an EXP/LOT number and GTIN code.*

FDA Label Image

Principal Display Panel (473 mL Bottle Label)

This is a medication guide for an oral solution containing 20mg of pregabalin per mL. It should be stored at room temperature and dispensed in child-resistant containers. The package insert should be consulted for dosage information. The solution is distributed by a company called Greenstone LLC.*

FDA Label Image

Principal Display Panel (473 mL Bottle Carton)

This is a medication guide for Pregabalin, a drug used to treat nerve pain, epilepsy, and anxiety disorder. It is for oral use only and should be dispensed in tight, child-resistant containers. The medication is manufactured by Greenstone LLC in Singapore and distributed in tight containers with 20mg of pregabalin per mL. The dosage information should be taken strictly as per the package insert. The available volume of the solution is 473 mL, which is dispensed with a medication guide.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.